Department of Health and Social Care

Data is not held on the number of National Health Service dental appointments offered each month.

As of 3 November 2025, there were nine NHS dentist practices in the Newton Abbot constituency, with two showing as ‘accepting new child patients when availability allows’ and two showing as ‘accepting new adult patients when availability allows’.

This data is sourced from the Find a Dentist website and is matched to constituencies based on the postcode data shown on the website, which is available at the following link:

https://www.nhs.uk/service-search/find-a-dentist

The data for the Devon Integrated Care Board (ICB), which includes the Newton Abbot constituency, shows that 29% of adults were seen by an NHS dentist in the previous 24 months up to June 2025, compared to 40% in England.

The responsibility for commissioning primary care services, including NHS dentistry, to meet the needs of the local population has been delegated to the ICBs across England.

Government responsibility for delivering brain cancer research is shared between the Department for Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation (UKRI). The Medical Research Council (MRC) funds fundamental discovery science through to the development and testing of new diagnostics, therapeutic interventions, and preventive measures whilst the NIHR funds applied health and care research that turns discoveries into new or improved treatments, diagnostics, medical technologies, or services.

To bridge the gap between early findings and clinical practice, the NIHR supports translational research focused on patient-centred research and healthcare. NIHR Biomedical Research Centres take leading-edge cancer research from the laboratory and rapidly translate it into clinical trials. The NIHR Innovation Observatory scans for new opportunities to identify emerging interventions or those with the potential for repurposing.

In September 2024, the NIHR announced a new approach to transform the outcomes for patients and their families who are living with brain tumours, ultimately reducing the lives lost to cancer. This will be done by maximising the United Kingdom’s clinical trials potential and working with the life sciences sector to make the UK a leading location for brain tumour research.

The UKRI offers a broad range of funding opportunities to support brain tumour research, including in partnership with industry. The MRC has actively engaged with brain tumour researchers to encourage applications The MRC has also identified the need for better disease models which informed a recent MRC-led funding opportunity to improve human in vitro models, and which resulted in two awards that will explore improving the use of human brain tumour tissue in research.

The Government is committed to furthering our investment and support for high-quality brain tumour research, ensuring that funding is used in the most meaningful and impactful way, and the NIHR continues to welcome further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to brain cancer.

The Department of Health and Social Care is committed to ensuring that all patients, including those with brain cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments. The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for those with brain cancer.

The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on brain cancer to take place in England, by ensuring the patient population can be more easily contacted by researchers.

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchairs services, based on the needs of their local population, including the offer of a personal health budget to enable a choice of wheelchair.

There are a range of providers of National Health Service wheelchair services across England. ICBs are responsible for monitoring service provision and effectively managing contracts with their commissioned providers. We expect local commissioning to be informed by the best available evidence, including guidance issued by NHS England.

NHS England is taking steps support ICBs and wheelchair providers to reduce regional variation in the quality and provision of NHS wheelchairs, and to support ICBs to reduce delays in people receiving timely intervention and wheelchair equipment. This includes publishing a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards relevant to all suppliers regardless of Care Quality Commission registration status, as well as statutory requirements for ICBs. The framework is available at the NHS.UK website, in an online only format.

The Wheelchair Quality Framework aligns with the Care Quality Commission’s assessment framework and supports the aims of integrated care systems to improve outcomes in population health and health care, and to tackle inequalities in outcomes, experiences, and access. The Care Quality Commission Assessment framework is available on the Care Quality Commission’s website, in an online only format.

The National Institute for Health and Care Excellence (NICE) plays a critical role in supporting patient access to clinically and cost effective new medicines and it consistently approves a very high proportion of medicines that come to England for appraisal. Over the last five years, NICE has approved 91% medicines that it appraised, with the latest figures for 2024/25 also standing at 91%.

NICE is also monitoring the proportion of appraisals that are terminated where the company does not participate in the appraisal process. The Medicines data: NICE approvals and availability in England paper, a copy of which is attached, was recently considered by the NICE board and summarised the findings of research with companies into the reasons stated by industry for terminating appraisals. The research showed that the proportion of terminations has been stable over the last five years, and that terminations reflect that not all products/indications will likely be clinically and cost effective.

The Life Sciences Sector Plan, published on 16 July, focuses on enabling world-class research and development, making the United Kingdom one of the best places in the world to start, scale, and invest in life sciences, thereby driving healthcare innovation and reform. This approach will support high-growth businesses, deliver better health outcomes, and cement the UK’s global leadership in life sciences.

It sets out our commitment to make the UK one of the top three fastest places in Europe for patient access to medicines by 2030. To achieve this, the Government will measure:

- the speed with which products are licensed and/or registered on the UK market in comparison to other European markets;

- the timeline and cost to achieving appropriate Health Technology Assessment in England; and

- the uptake and widespread adoption of products in the National Health Service in England.

The Department has not made a specific assessment of the Welsh Government’s project to build a reactor for medical radioisotope manufacture.

The Department regularly engages with suppliers, specialist clinicians, the British Nuclear Medicine Society, and the UK Radiopharmacy Group to support the continued supply of medical radioisotopes for National Health Services.

NHS England has no plans to mandate the framework for National Health Services. Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchairs services, based on the needs of their local population. We expect local commissioning to be informed by the best available evidence, including guidance issued by NHS England.

NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services. On 9 April 2025, NHS England published a Wheelchair Quality Framework which sets out quality standards relevant to all suppliers regardless of Care Quality Commission registration status, as well as statutory requirements for ICBs. The framework is available at the NHS.UK website, in an online only format.

In accordance with the NHS Federated Data Platform Check and Challenge Group’s terms of reference, NHS England aims to publish minutes within two months, to allow time for the group to check and agree the notes at their following meeting. I would therefore expect the minutes from this meeting to be available on the NHS England website by the end of November 2025.

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchairs services, based on the needs of their local population, and NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services. Any equipment provided will be agreed following a clinical assessment and based on the needs identified.

NHS England is taking steps to reduce regional variation in the quality and provision of National Health Service wheelchairs, including any specialist electric wheelchair provision, and to support ICBs to reduce delays in people receiving timely intervention and wheelchair equipment. These include: establishing a national wheelchair data set which looks at waiting times across the pathway to enable targeted action if improvement is required; publishing a wheelchair quality framework which sets out quality standards relevant to all suppliers; and the introduction of personal wheelchair budgets to give people greater choice in the selection of manual and electric wheelchairs.

Genomic testing in the National Health Service in England is delivered through the NHS Genomic Medicine Service (GMS) via seven regional Genomic Laboratory Hubs (GLHs). All seven GLHs deliver testing based on the National Genomic Test Directory, which outlines eligibility criteria for genomic testing, including whole genome sequencing. NHS England monitors testing activity and performance through Patient Level Contract Monitoring data across all seven GLHs, enabling NHS England to identify variation and work with the GLHs to implement improvements. Seven NHS GMS Alliances also work to embed genomics into clinical pathways, raise awareness among clinicians and the public, and ensure equitable access to whole genome sequencing across all regions.

Oversight of wheelchair services within the National Health Service and social care is provided by national bodies, which monitor different aspects of the market, and by local authorities.

NHS England supports the integrated care boards (ICBs) to commission effective, efficient, and personalised wheelchair services. This includes taking steps support ICBs and wheelchair providers to reduce regional variation in the quality and provision of NHS wheelchairs. NHS England published a Wheelchair Quality Framework on 9 April 2025, which sets out the quality standards relevant to all suppliers regardless of Care Quality Commission registration status, and statutory requirements for ICBs. The framework is available on the NHS.UK website, in an online only format.

The Government has put in place a range of initiatives to help NHS bodies make informed choices about the products and the route through which they are bought. These include the NHS Supply Chain, a national body which is responsible for procuring and delivering the majority of equipment into the NHS. The NHS Supply Chain was set up to leverage the collective buying power of the NHS, to drive savings and provide a standardised range of clinically assured quality products at the best value.

ICBs are responsible for commissioning wheelchair services, based on the need of their local population, and for having sufficient expertise to commission high quality services. ICBs will assess the market when securing local provision. This includes monitoring service provision and effectively managing contracts with their commissioned providers.

Local authorities are responsible for providing equipment that supports daily living and independence. Under the Care Act 2014, local authorities are tasked with the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouraging a wide range of service provision to ensure that people have a choice of appropriate services and equipment that maximise independence and put the wellbeing of the people who draw on care at the centre of decisions.

Oversight of wheelchair services within the National Health Service and social care is provided by national bodies, which monitor different aspects of the market, and by local authorities.

NHS England supports the integrated care boards (ICBs) to commission effective, efficient, and personalised wheelchair services. This includes taking steps support ICBs and wheelchair providers to reduce regional variation in the quality and provision of NHS wheelchairs. NHS England published a Wheelchair Quality Framework on 9 April 2025, which sets out the quality standards relevant to all suppliers regardless of Care Quality Commission registration status, and statutory requirements for ICBs. The framework is available on the NHS.UK website, in an online only format.

The Government has put in place a range of initiatives to help NHS bodies make informed choices about the products and the route through which they are bought. These include the NHS Supply Chain, a national body which is responsible for procuring and delivering the majority of equipment into the NHS. The NHS Supply Chain was set up to leverage the collective buying power of the NHS, to drive savings and provide a standardised range of clinically assured quality products at the best value.

ICBs are responsible for commissioning wheelchair services, based on the need of their local population, and for having sufficient expertise to commission high quality services. ICBs will assess the market when securing local provision. This includes monitoring service provision and effectively managing contracts with their commissioned providers.

Local authorities are responsible for providing equipment that supports daily living and independence. Under the Care Act 2014, local authorities are tasked with the duty to shape their care market and to commission a range of high-quality, sustainable, and person-centred care and support services to meet the diverse needs of all local people. This includes encouraging a wide range of service provision to ensure that people have a choice of appropriate services and equipment that maximise independence and put the wellbeing of the people who draw on care at the centre of decisions.

NHS England has produced national sample handling guidance for the whole genome sequencing (WGS) of solid tumours, including brain tumours, to standardise collection, processing, and transport. This guidance supports collaboration between neurosurgeons, pathologists, and Genomic Laboratory Hubs to maintain DNA quality and improve access to WGS. Approaches to the handling of fresh tissue have been reviewed, including the use of tissue stabilisers, to reduce some of the barriers of having to acquire, freeze, and transport the frozen tissue, which in turn will speed up processes. These measures aim to address variability and ensure equitable regional access to WGS for brain tumour patients.

The NHS Cancer Vaccine Launch Pad (CVLP) is a platform that aims to accelerate the development of cancer vaccines and speed up cancer patient access to mRNA personalised cancer vaccine clinical trials. The CVLP has played a key role in accelerating trial activity in cancer research, with CVLP sites driving faster site activation and enrolment timelines. The platform is company- and clinical trial- agnostic. The CVLP would encourage any company that wishes to deliver trials via the platform, including those developing personalised cancer vaccines for brain tumours, to get in contact to explore how the platform can support their research.

The Government is empowering local leaders with the autonomy they need to provide the best services to their local community, including for those with dementia.

That is why we have published the D100: Assessment Tool Pathway programme, which brings together multiple resources into a single, consolidated tool. This will help simplify best practice for system leaders and help create communities and services where the best possible care and support is available to those with dementia. The tool is available at the following link:

https://www.rcpsych.ac.uk/improving-care/nccmh/service-design-and-development/dementia-100-pathway-assessment-tool

We will also deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia, and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.

The Government recognises the vital role of unpaid carers and is committed to ensuring they have the support they need.

The Care Act 2014 requires local authorities to deliver a wide range of sustainable, high-quality care and support services, which can include respite support for carers.

To help local authorities fulfil their duties, including to unpaid carers, the 2025 Spending Review allows for an increase of over £4 billion of funding available for adult social care in 2028/29 compared to 2025/26.

The Darzi Investigation found that there are too many targets set for the National Health Service, which made it hard for local systems to prioritise their actions or to be held properly accountable.

Our aim is to give more power to local systems and let them decide how they use local funding to best meet the needs of their local population.

NHS Planning Guidance is not an exhaustive list of everything the NHS does, and the absence of a target does not mean it is not an area of focus. We remain committed to recovering the dementia diagnosis rate to the national ambition of 66.7%.

We will deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in the quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia, and will set national standards for dementia care and redirect NHS priorities to provide the best possible care and support.

National Health Service orthodontic treatment is free for people under the age of 18 years old with a clear health need for treatment. Adult patients, and patients under the age of 18 years old who do not qualify for NHS orthodontic treatment, may choose to pay for private orthodontic treatment. Further information can be found at the following link:

https://www.nhs.uk/tests-and-treatments/orthodontics/#:~:text=Taking%20care%20of%20your%20teeth,of%20your%20teeth%20and%20gums

The responsibility for commissioning primary care services, including NHS dentistry and orthodontic services, to meet the needs of the local population has been delegated to the integrated care boards (ICBs) across England. For the Hornsey and Friern Barnet constituency, this is the North Central London ICB.

We want all health and care staff to have received the appropriate training to provide high quality care to people with dementia. Employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver appropriate treatment for patients.

The required training needs are set out in the Dementia Training Standards Framework, which is available at the following link:

https://www.skillsforhealth.org.uk/info-hub/dementia-2015-updated-2018/

There are a variety of resources available on the NHS England E-learning for Health platform, including a programme on dementia care, designed to enhance the training and education of the health and social care workforce

Our health system has struggled to support those with complex needs, including those with dementia. Under the 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.

We will deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia and will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.

We are expanding capacity in general practice, enabling more appointments for patients both nationally and in Gloucestershire.

Gloucestershire Integrated Care Board has achieved a 6.4% increase in appointments delivered in general practice since 2024, with 398,000 appointments provided in September 2025 compared to 374,000 in September 2024.

In October 2024, we invested £82 million into the Additional Roles Reimbursement Scheme to support the recruitment of an additional 2,500 GPs into Primary Care Networks across England. This has helped to increase appointment availability and improve care for thousands of patients. We have invested an additional £1.1 billion in general practice to reinforce the front door of the National Health Service which was the biggest increase in over a decade. Additionally, we have invested £102 million into the Primary Care Utilisation and Modernisation Fund which will create additional clinical space within over 1,000 GP practices across England and will help deliver more appointments each year.

We are aware of the challenges faced in accessing a National Health Service dentist including for carers and front-line workers. We have asked integrated care boards (ICBs) to commission extra urgent dental appointments from 1 April 2025.

ICBs are also recruiting dentists through the Golden Hello scheme. This recruitment incentive will see dentists receiving payments of £20,000 to work in those areas that need them most for three years.

We are committed to reforming the dental contract, with a focus on matching resources to need, improving access, promoting prevention and rewarding dentists fairly, while enabling the whole dental team to work to the top of their capability. The Government is committed to achieving fundamental contract reform before the end of this Parliament.

We recently held a full public consultation on a package of changes to improve access to, and the quality of NHS dentistry, which will deliver better care for the diverse oral health needs of people across England. The consultation closed on 19 August 2025. The Government is considering the outcomes of the consultation and will publish a response in due course.

The Department is expanding capacity in general practice which will help deliver more appointments to patients, ensuring everyone, including those in full-time employment and with caring responsibilities, can access care.

General practitioner (GP) core hours are between 8am and 6:30pm Monday to Friday, extending beyond the usual working day and usual school day to allow easier access for those in employment, or with caring responsibilities.

In October 2024, we invested £82 million into the Additional Roles Reimbursement Scheme to support the recruitment of over 2,000 additional GPs into primary care networks (PCNs) across England, helping to increase appointment availability. In addition, practices are now required to provide access to online services throughout core operating hours, reducing the 8am scramble and increasing flexibility for patients.

PCNs must also offer appointments outside of core hours, including on weekends, which can be more convenient for people in full-time employment, or with caring responsibilities.

Our health system has struggled to support those with complex needs, including those with dementia. Under our 10-Year Health Plan, those living with dementia will benefit from improved care planning and better services.

We will deliver the first ever Frailty and Dementia Modern Service Framework to deliver rapid and significant improvements in quality of care and productivity. This will be informed by phase one of the independent commission into adult social care, expected in 2026.

The Frailty and Dementia Modern Service Framework will seek to reduce unwarranted variation and narrow inequality for those living with dementia. It will set national standards for dementia care and redirect National Health Service priorities to provide the best possible care and support.

Those with dementia will also benefit from more joined up care through co-created care plans.

We have also published the D100: Assessment Tool Pathway programme, which brings together multiple resources into a single, consolidated tool to help simplify best practice. This is available at the following link:

https://www.rcpsych.ac.uk/improving-care/nccmh/service-design-and-development/dementia-100-pathway-assessment-tool

We are determined to rebuild National Health Service dentistry, but it will take time and there are no quick fixes. Strengthening the workforce is key to our ambitions.

To rebuild dentistry in the long term, we will reform the dental contract, with a shift to focus on prevention and the retention of NHS dentists. The Government’s ambition is to deliver fundamental contract reform before the end of this Parliament.

Integrated care boards are recruiting more dentists through the Golden Hello scheme. This recruitment incentive will see dentists receiving payments of £20,000 to work in those areas that need them most for three years.

As announced in our 10-Year Health Plan, the Government will make it a requirement for newly qualified dentists to practice in the NHS for a minimum period, intended to be at least three years. That will mean more NHS dentists and more NHS appointments.

We will also publish a 10 Year Workforce Plan and ensure the NHS has the right people in the right places, with the right skills to deliver the best care for patients, when they need it.

Dental amalgam is a well-established, safe, and effective dental filling material. Current Department policy is to restrict and phase down the use of dental amalgam to reduce any environmental impacts. This includes regulations to ban the use of amalgam in baby teeth, pregnant and breastfeeding women, and children under 15 years old, except when deemed strictly necessary for specific medical needs. This has been in place since 2018.

The United Kingdom is party to the Minamata Convention on Mercury, a global treaty to protect human health and the environment from the adverse effects of mercury. The Minamata Convention has recommended that those party to the convention phase down the use of dental amalgam, which the UK does, for example, by restricting its use in under 15-year-olds.

The sixth meeting of the Conference of the Parties to the Minamata Convention is taking place from 3 November to 7 November 2025, where a ban on mercury dental amalgam will be discussed.

We know that some patients may struggle or prefer not to use digital options. We are committed to ensuring that patients who are digitally excluded can retain telephone and in-person routes to book general practice (GP) appointments, by mandating that GPs must maintain these traditional access methods, alongside digital options. The move to digital-first access is designed to free up phone lines for those who want and need them, not replace them.

Palliative care services, including children’s palliative care services, are included in the list of services an integrated care board (ICB) must commission. To support ICBs, including the Lincolnshire ICB, in this duty, NHS England has published statutory guidance and a service specification for children and young people. The statutory guidance states that ICBs must work to ensure that there is sufficient provision of care services to meet the needs of their local populations.

The Department and NHS England are currently working at pace to develop plans on how best to improve the access, quality, and sustainability of all-age palliative care and end of life care in line with the 10-Year Health Plan.

Whilst the majority of palliative care and end of life care is provided by National Health Service staff and services, we recognise the vital part charitable hospices play as well. This is why we are supporting the hospice sector with a £100 million capital funding boost for eligible adult and children’s hospices in England to ensure they have the best physical environment for care. St Andrew’s Hospice, which serves children in Lincolnshire, is receiving £370,356 from this funding.

We are also providing £26 million in revenue funding to support children and young people’s hospices for 2025/26. St Andrew’s Hospice is receiving £372,000 from this funding.

I am pleased to confirm the continuation of approximately £26 million, adjusted for inflation, for the next three financial years, from 2026/27 to 2028/29 inclusive, to be distributed again via ICBs. This amounts to approximately £80 million over the next three years.

The Food Hygiene Rating Scheme (FHRS) is a consumer information scheme operated by the Food Standards Agency (FSA) in partnership with local authorities across England, Wales, and Northern Ireland. Ultimately, it is the responsibility of businesses to comply with food hygiene law at all times. However, the FSA provides Safer Food Better Business guidance to help small businesses manage food hygiene, and there is an information pack specifically for caterers at the following link:

https://www.food.gov.uk/business-guidance/safer-food-better-business-for-caterers

The FSA also publishes guidance on inspections, the FHRS, and how to achieve the top rating. This guidance is available at the following link:

https://www.food.gov.uk/business-guidance/preparing-for-your-first-food-hygiene-inspection

Businesses with low ratings will continue to receive follow up action or visits by local authorities to ensure that non-compliances are addressed. If the local authority officer finds that a business’s hygiene standards are very poor and food may be unsafe to eat, they must act to protect consumers. This could result in stopping part of the business or closing it down completely until it is safe to reopen it.

In the very rare event where someone may have suffered a severe adverse reaction to a vaccine, care and treatment will be best managed by local National Health Service specialist services, augmented as appropriate by national specialist advice. Individuals will be treated and managed through existing healthcare services, with treatment dependent on the individual’s clinical needs.

Individuals can also apply to the Vaccine Damage Payment Scheme (VDPS) which provides a one-off, tax-free payment of £120,000 to claimants who have been found, on the balance of probabilities, to have been severely disabled as a result of vaccinations against certain diseases listed in the Vaccine Damage Payments Act 1979.

Outside of the VDPS, other Government support remains available for those with a disability or long-term health condition, including Statutory Sick Pay, Universal Credit, Employment and Support Allowance, Attendance Allowance, and Personal Independence Payments. Further information is available at the following link:

https://www.gov.uk/browse/benefits/disability

The Government is committed to improving the lives of those living with rare diseases and continues to make progress under the UK Rare Diseases Framework. Mental health and psychological support has featured as a focus area under England’s rare diseases action plans, the most recent of which was published in February 2025. Access to psychological support for people with rare diseases is underpinned by National Health Service service specifications. In addition, the NHS National Genomics Education Programme provides information to health care professionals, including on mental health and rare disease. This includes setting out how the mental health of rare disease patients requires assessment, and that monitoring should be an integral part of care plans, considered equally as important as physical health.

More widely, the 10-Year Health Plan sets out ambitious plans to transform mental health services to improve access and treatment, and to promote good mental health and wellbeing for the nation. This includes improving assertive outreach, investing in mental health emergency departments and neighbourhood mental health centres, and increasing access to talking therapies and evidence-based digital interventions.

The National Health Service operates an Integrated Community Stroke Service at Camborne Redruth Community Hospital. This service provides specialist therapy, advice, and support for people, their families, and carers following stroke and transient ischaemic attack or mini stroke.

To improve outcomes for patients with stroke and transient ischaemic attacks, the Government will publish a cardiovascular disease modern service framework. This will identify and set standards for the best evidenced interventions, drive innovation in stroke prevention and management, and reduce unwarranted variation in healthcare.

The UK Health Security Agency undertakes monitoring and surveillance of HIV and hepatitis B and C viral infections, including new diagnoses. This includes regional and demographic information that is published through a series of surveillance reports.

A regional breakdown of new HIV diagnoses can be accessed in the HIV diagnoses, AIDS, deaths and people in care: country and region tables, United Kingdom, 2015 to 2024 table, a copy of which is attached. In addition, demographic data is available in the HIV diagnoses, AIDS, deaths and people in care: key population HIV tables, England, 2015 to 2024 table, a copy of which is also attached.

Acute hepatitis B surveillance reports can be accessed at the following link:

https://www.gov.uk/government/publications/acute-hepatitis-b-england-enhanced-surveillance-reports

Hepatitis C laboratory reports are published annually at the following link:

https://www.gov.uk/government/publications/hepatitis-c-england-and-wales-2024/laboratory-reports-of-hepatitis-c-infections-in-england-and-wales-april-to-june-2024

The Department’s Fingertips tool also provides publicly accessible geographical information on hepatitis B and C and HIV, and is available at the following link:

https://fingertips.phe.org.uk/search/hepatitis

The Core20PLUS5 is a national approach to inform action to reduce healthcare inequalities at a system level. The approach defines a target population, the Core20PLUS, and five clinical areas to focus on that require accelerated improvement. PLUS population groups should be identified at a local level. NHS England expects to see learning disability identified as a priority cohort.

The Healthcare Inequalities Improvement Programme has worked closely with NHS England’s clinical programmes to develop and embed indicators which enable the monitoring of the access, experience, and outcomes for Core20PLUS populations, and this includes people with a learning disability. The Core20PLUS5 indicator for learning disability is the Percentage of patients aged 14+ on GP learning disability registers who received an annual health check.

NHS England has published a Statement on Information on Health Inequalities which sets out the data that integrated care boards (ICBs) are expected to collect. This includes that ICBs should publish in their 2023/24 and 2024/25 annual reports relating to learning disability annual health checks and adult mental health inpatient rates for people with a learning disability and autistic people. Within these annual reports, it is expected that ICBs should explain how the information has been used to guide action.

In addition, each ICB must have an executive lead for learning disability and autism who will support the board in addressing health inequalities, supporting equal access to care across all health services, and improving overall health outcomes.

The Core20PLUS5 is a national approach to inform action to reduce healthcare inequalities at a system level. The approach defines a target population, the Core20PLUS, and five clinical areas to focus on that require accelerated improvement. PLUS population groups should be identified at a local level. NHS England expects to see learning disability identified as a priority cohort.

The Healthcare Inequalities Improvement Programme has worked closely with NHS England’s clinical programmes to develop and embed indicators which enable the monitoring of the access, experience, and outcomes for Core20PLUS populations, and this includes people with a learning disability. The Core20PLUS5 indicator for learning disability is the Percentage of patients aged 14+ on GP learning disability registers who received an annual health check.

NHS England has published a Statement on Information on Health Inequalities which sets out the data that integrated care boards (ICBs) are expected to collect. This includes that ICBs should publish in their 2023/24 and 2024/25 annual reports relating to learning disability annual health checks and adult mental health inpatient rates for people with a learning disability and autistic people. Within these annual reports, it is expected that ICBs should explain how the information has been used to guide action.

In addition, each ICB must have an executive lead for learning disability and autism who will support the board in addressing health inequalities, supporting equal access to care across all health services, and improving overall health outcomes.

The Government’s 10-Year Health Plan sets out to tackle health inequalities and people with disabilities are a priority for care from a neighbourhood team with more holistic, on-going support. Ahead of this, action is underway to improve access and support through staff training, proactive health checks and plans, and the Mental Health Act reforms.

The Government knows that people with a learning disability and autistic people have poorer health outcomes than the general population, including, on average, dying younger. They continue to experience disparities in the quality of care they receive, which may include barriers to accessing the right support.

The Government is rolling out the Oliver McGowan Mandatory Training on Learning Disability and Autism to the health and adult social care workforce to ensure staff have the right knowledge and skills to provide safe, informed care. Oliver’s Training is the Government’s preferred package for providers registered with the Care Quality Commission to meet the statutory training requirement under the Health and Care Act 2022. Over three million people have completed the e-learning package, the first part of this training, and more than 2,700 people have been trained to deliver the interactive second part nationwide.

Annual health checks for people with a learning disability are a crucial way to identify undetected conditions early and ensure the appropriateness of ongoing treatments. NHS England is working with people with lived experience, clinical professionals, and commissioners to produce a quality framework to ensure that these vital checks are high-quality. NHS England is also taking forward a range of work to improve the quality of the services accessed by people with a learning disability, including rollout of the Reasonable Adjustment Digital Flag across health and care services which enables health and publicly funded care professionals to record, share, and view details of the reasonable adjustments which individuals need to support their care and treatment.

The number of people with a learning disability and autistic people in mental health hospitals is unacceptable, and there are still too many people being detained who could be supported to live well in their communities. The Mental Health Bill currently before Parliament limits the scope of the ability to detain people with a learning disability and autistic people so that they can only be detained under Part 2, section 3 if they have a co-occurring mental disorder that requires hospital treatment. It also introduces measures to improve community support, including putting Care (Education) and Treatment Reviews and Dynamic Support Registers on a statutory footing, and placing certain duties on integrated care boards and local authorities when exercising existing commissioning duties.

The Government’s 10-Year Health Plan sets out to tackle health inequalities and people with disabilities are a priority for care from a neighbourhood team with more holistic, on-going support. Ahead of this, action is underway to improve access and support through staff training, proactive health checks and plans, and the Mental Health Act reforms.

The Government knows that people with a learning disability and autistic people have poorer health outcomes than the general population, including, on average, dying younger. They continue to experience disparities in the quality of care they receive, which may include barriers to accessing the right support.

The Government is rolling out the Oliver McGowan Mandatory Training on Learning Disability and Autism to the health and adult social care workforce to ensure staff have the right knowledge and skills to provide safe, informed care. Oliver’s Training is the Government’s preferred package for providers registered with the Care Quality Commission to meet the statutory training requirement under the Health and Care Act 2022. Over three million people have completed the e-learning package, the first part of this training, and more than 2,700 people have been trained to deliver the interactive second part nationwide.

Annual health checks for people with a learning disability are a crucial way to identify undetected conditions early and ensure the appropriateness of ongoing treatments. NHS England is working with people with lived experience, clinical professionals, and commissioners to produce a quality framework to ensure that these vital checks are high-quality. NHS England is also taking forward a range of work to improve the quality of the services accessed by people with a learning disability, including rollout of the Reasonable Adjustment Digital Flag across health and care services which enables health and publicly funded care professionals to record, share, and view details of the reasonable adjustments which individuals need to support their care and treatment.

The number of people with a learning disability and autistic people in mental health hospitals is unacceptable, and there are still too many people being detained who could be supported to live well in their communities. The Mental Health Bill currently before Parliament limits the scope of the ability to detain people with a learning disability and autistic people so that they can only be detained under Part 2, section 3 if they have a co-occurring mental disorder that requires hospital treatment. It also introduces measures to improve community support, including putting Care (Education) and Treatment Reviews and Dynamic Support Registers on a statutory footing, and placing certain duties on integrated care boards and local authorities when exercising existing commissioning duties.

The Government’s 10-Year Health Plan sets out to tackle health inequalities and people with disabilities are a priority for care from a neighbourhood team with more holistic, on-going support. Ahead of this, action is underway to improve access and support through staff training, proactive health checks and plans, and the Mental Health Act reforms.

The Government knows that people with a learning disability and autistic people have poorer health outcomes than the general population, including, on average, dying younger. They continue to experience disparities in the quality of care they receive, which may include barriers to accessing the right support.

The Government is rolling out the Oliver McGowan Mandatory Training on Learning Disability and Autism to the health and adult social care workforce to ensure staff have the right knowledge and skills to provide safe, informed care. Oliver’s Training is the Government’s preferred package for providers registered with the Care Quality Commission to meet the statutory training requirement under the Health and Care Act 2022. Over three million people have completed the e-learning package, the first part of this training, and more than 2,700 people have been trained to deliver the interactive second part nationwide.

Annual health checks for people with a learning disability are a crucial way to identify undetected conditions early and ensure the appropriateness of ongoing treatments. NHS England is working with people with lived experience, clinical professionals, and commissioners to produce a quality framework to ensure that these vital checks are high-quality. NHS England is also taking forward a range of work to improve the quality of the services accessed by people with a learning disability, including rollout of the Reasonable Adjustment Digital Flag across health and care services which enables health and publicly funded care professionals to record, share, and view details of the reasonable adjustments which individuals need to support their care and treatment.

The number of people with a learning disability and autistic people in mental health hospitals is unacceptable, and there are still too many people being detained who could be supported to live well in their communities. The Mental Health Bill currently before Parliament limits the scope of the ability to detain people with a learning disability and autistic people so that they can only be detained under Part 2, section 3 if they have a co-occurring mental disorder that requires hospital treatment. It also introduces measures to improve community support, including putting Care (Education) and Treatment Reviews and Dynamic Support Registers on a statutory footing, and placing certain duties on integrated care boards and local authorities when exercising existing commissioning duties.

The Government is taking a range of actions to improve participation in breast screening in Devon, through the NHS Breast Screening Programme. These actions include:

• creating videos for different audiences, such as people with a learning disability or dementia;
• collaborating with local schools to provide information and promote breast screening awareness;
• contacting patients who do not attend their booked appointment to understand the reasons for non-attendance, and addressing barriers on an individual level to support attendance;
• sending text messages to remind patients of appointments;
• offering a chaperone service to individuals who are nervous about attending their appointment; and
• collaborating with a local menopause nurse to raise awareness of breast screening.

I am aware that the marketing authorisation holder has established an early access programme (EAP) through which some NHS patients are currently accessing tofersen. This is a company-led EAP and therefore the Department nor NHS England centrally hold prospective information regarding the exact number of patients receiving tofersen.

Through the National Institute for Health and Care Research (NIHR), the Department has funded and supported multiple studies investigating urinary tract infections (UTIs), with some funded studies studying the link between UTIs and cognitive outcomes. For example, NIHR has funded the ‘IntraVESical Preparations for REcurrent Urinary Tract Infection Prevention’ (VESPER) study. This study aims to determine whether in-bladder treatments are more effective and cost-efficient than second-line oral antibiotics in reducing recurrent UTIs in women who have not responded to first-line preventative antibiotics. It will connect clinical outcomes with quality-adjusted life year (QALY)-based evaluations that take cognitive changes into account.

NIHR infrastructure is also conducting relevant research that is investigating UTIs and considering cognitive outcomes. The NIHR Southampton Biomedical Research Centre, is leading the ‘DIagnoSing Care hOme UTI’ (DISCO UTI) study which is investigating new ways to accurately diagnose and treat UTIs in care homes, as UTIs can cause symptoms like confusion, resulting in difficulties when diagnosing UTIs in care home residents.

The National Institute for Health and Care Excellence (NICE) has recommended a number of weight-loss medicines for use on the National Health Service, which the NHS is now required to fund for eligible patients in line with NICE’s recommendations, including for women with polycystic ovary syndrome and fertility problems.

The product information for weight loss medicines state that all individuals of child-bearing potential, who are able to become pregnant, using GLP-1 medications should take steps to ensure they do not become pregnant. GLP-1 medicines should not be taken during pregnancy or just before trying to get pregnant.

The NHS is currently rolling out tirzepatide for obesity in primary care, using a phased approach based on clinical need to manage NHS resources. Around 220,000 individuals are expected to be eligible over the next three years. NHS England worked with clinical experts, integrated care boards, patient and public representatives, healthcare professionals, charities and royal colleges on its prioritisation approach, which it set out in its interim commissioning guidance, available at the following link:

https://www.england.nhs.uk/publication/interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-nice-funding-variation-for-tirzepatide-mounjaro-for-the-management-of-obesity/

At the current time, patients will be eligible for treatment in primary care if they have a body mass index of at least forty, and four or more out of five ‘qualifying' conditions. The qualifying conditions are cardiovascular disease, hypertension, dyslipidaemia, obstructive sleep apnoea, and type 2 diabetes mellitus.

Hospital discharge and the numbers of people discharged on pathways 0-3 are monitored on a regular basis and figures are published monthly by NHS England via the Acute Discharge Situation Report. The reports are available at the following link:

https://www.england.nhs.uk/statistics/statistical-work-areas/discharge-delays/acute-discharge-situation-report/

Data from 2022/23 and 2023/24 shows a general increase in discharges over the two years, but the proportion of people being discharged to each pathway remain relatively stable between the summer period, from April to September, and winter periods, from October to March. Definitions for data collected on discharge pathways changed from 27 May 2024 onwards, and figures from before and after this date are therefore not directly comparable.

To support areas to achieve timely hospital discharge, this Government published a new policy framework in January 2025 for the £9 billion Better Care Fund, which provides the National Health Service and local authorities accountability for setting and achieving joint goals for reducing discharge delays, preventing avoidable emergency admissions and care home admission. Some challenged systems in need of additional support are also receiving a programme of improvement support.

There are no plans to introduce a separate evaluation process for orphan medicines. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether all new licensed medicines, including medicines for rare diseases, should be routinely funded by the NHS based on an assessment of their costs and benefits. NICE operates a separate highly specialised technologies programme for the evaluation of a small number of treatments for very rare, very severe diseases which uses a much higher cost-effectiveness threshold that recognises the challenges of bringing treatments for very rare diseases to market.

NICE’s methods have been proven to be suitable for the evaluation of rare disease medicines, where companies are willing to price their medicines fairly. NICE’s approval rate for medicines for rare diseases is in line with its overall approval rate for new medicines, and from April 2024 to April 2025, NICE recommended all 15 of the rare disease drugs that it evaluated through its standard technology appraisal programme.

There are no plans to introduce a separate evaluation process for orphan medicines. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether all new licensed medicines, including medicines for rare diseases, should be routinely funded by the NHS based on an assessment of their costs and benefits. NICE operates a separate highly specialised technologies programme for the evaluation of a small number of treatments for very rare, very severe diseases which uses a much higher cost-effectiveness threshold that recognises the challenges of bringing treatments for very rare diseases to market.

NICE’s methods have been proven to be suitable for the evaluation of rare disease medicines, where companies are willing to price their medicines fairly. NICE’s approval rate for medicines for rare diseases is in line with its overall approval rate for new medicines, and from April 2024 to April 2025, NICE recommended all 15 of the rare disease drugs that it evaluated through its standard technology appraisal programme.

The Medicines and Healthcare products Regulatory Agency have confirmed that the response received from the Swedish Medical Products Agency in relation to the 2008 assessment of preclinical data published within FOI 24/015 did not contain an offer to contact psychiatrists responsible for the care of children and teenagers.